Abstract
Interaction with DNA is supposed to play an essential role in the cytostatic effects of platinum anti-tumor drugs like cisplatin (cisDDP) and carboplatin (CBDCA). Clinical resistance to cisplatin and carboplatin, both primary and acquired, might be related to decreased levels of DNA adduct formation and/or increased capacities to repair these adducts. We have studied DNA adduction by cisplatin and carboplatin at the level of the single cell. In the last decade, methods have been developed for the immunocytochemical analysis of DNA modifications induced by a variety of carcinogens, anti-cancer drugs and radiation [see Den Engelse et al., 1990 for review].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Den Engelse, L., van Benthem, J. and Scherer, E. (1990) Immunocytochemical analysis of in vivo DNA modification. Mut. Res., 233, 265–287.
Fichtinger-Schepman, A.M.J., van Oosterom, A.T., Lohman, P.H. M. and Berends, F. (1987) cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res., 47, 3000–3004.
Gill, I., Muggia, F.M., Terheggen, P., Michael, C, Parker, R.J., Kortes, V., Grunberg, S., Christian, M.C., Reed, E. and den Engelse, L. (1991) Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): Tolerance and relation to leukocyte and buccal cell platinum-DNA adducts. Annals Oncol., in press.
Knox, R.J., Friedlos, F., Lydall, D.A. and Roberts, J.J. (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46, 1972–1979.
Poirier, M.C., Reed, E., Zwelling, L.A., Ozols, R.F., Litterst, C.L. and Yuspa, S.H. (1985) Polyclonal antibodies to quantitate cis-diamminedichloroplatinum((II)-DNA adducts in cancer patients and animal models. Environ. Health Perspect., 62, 89–94.
Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H. and Poirier, M.C. (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci., 84, 5024–5028.
Reed, E., Yuspa, S.H., Zwelling, L.A., Ozols, R.F. and Poirier, M.C. (1986) Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest., 77, 545–550.
Safirstein, R., Winston, J., Moel, D., Dikman, S. and Guttenplan, J. (1987) Cisplatin nephrotoxicity: insight into mechanism. Int. J. Androl., 10, 325–346.
Terheggen, P.M.A.B. (1989) Interaction of cisplatin and carboplatin with cellular DNA. Thesis, Leiden.
Terheggen, P.M.A.B., Begg, A.C, Emondt, J.Y., Dubbelman, R., Floot, B.G.J. and den Engelse, L. (1991) Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. Br. J. Cancer, 63, in press.
Terheggen, P.M.A.B., Begg, A.C, Floot, B.G.J., Emondt, J. and den Engelse, L. (1988a). Visualization of cisplatin-DNA and carboplatin-DNA adducts in tissues and cultured cells. In: Proc. 5th. Int. Symp. on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Padua, Italy, 1987, Nicolini, M. (ed.), Martinus Nijhoff, Boston, pp. 139–143.
Terheggen, P.M.A.B., Dijkman, R., Begg, A.C, Dubbelman, R., Floot, B.G.J., Hart, A.A.M. and den Engelse, L. (1988) Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res., 48, 5597–5603.
Terheggen, P.M.A.B., Emondt, J.Y., Floot, B.G.J., Dijkman, R., Schrier, P.I., den Engelse, L. and Begg, A.C. (1990) Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res., 50, 3556–3561.
Terheggen, P.M.A.B., Floot, B.G.J., Scherer, E., Begg, A.C, Fichtinger-Schepman, A.M.J. and den Engelse, L. (1987) Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections. Cancer Res., 47, 6719–6725.
Terheggen, P., Reed, E., Michael, C, Begg, A., Muggia, F. and den Engelse, L. (1990) Platinum-DNA binding in patients treated with cisplatin and carboplatin. Proc. Am. Assoc. Cancer Res., 31, 334.
Van Schooten, F.J., Hillebrand, M.J.X., Scherer, E., den Engelse, L. and Kriek, E. (1991) Immunocytochemical visualization of DNA adducts in mouse tissues and human white blood cells following treatment with benzo[a]pyrene or its diol epoxide. A guantitative approach. Carcinogenesis, 12, 427–433.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
den Engelse, L., Schornagel, J., Blommaert, F., Terheggen, P. (1991). Immunocytochemical Analysis of Platinum-DNA Adducts. In: Howell, S.B. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0738-7_26
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0738-7_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0740-0
Online ISBN: 978-1-4899-0738-7
eBook Packages: Springer Book Archive